Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1003 (Nofazinlimab) + Lenvatinib vs Placebo + Lenvatinib in Advanced HCC
2024-517331-48-00Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing CS1003 (Nofazinlimab) + Lenvatinib with Placebo + Lenvatinib (2 arms). Primary endpoint: Overall survival. Started Oct 2024; status: completed.
02
Drugs
nofazinlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-517331-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517331-48-00.